cd38xcd3 | Igm-2644, a Novel CD38xCD3 Bispecific IgM T Cell Engager �

Keyword	CPC	PCC	Volume	Score	Length of keyword
cd38xcd3	1.37	1	4552	8	8

Keyword	CPC	PCC	Volume	Score
cd38 cd31	0.43	1	2518	59
cd38 cd39	1.75	0.9	7758	32
cd38xcd28	1.07	0.3	3283	43
cd38 cd34	0.93	0.8	7955	90
cd38 cd3 cd28	1.46	0.8	198	97
cd38 x cd16 x hsa	1.19	1	8985	44
cd38 cd47	1.27	0.9	7243	48
cd38cd24	1.76	0.3	141	23
cd38 cd45	1.58	0.7	1455	80
cd38cd27	1.03	0.1	8234	10
cd38 cd138	0.53	0.7	2413	27
cd38 cd19	0.39	0.7	7037	20
cd38 cd157	0.9	0.1	3807	47
cd38 cd101	0.59	0.1	3920	82
cd38 cd16	0.69	0.7	1514	34
cd38 cd138 multiple myeloma	1.02	0.2	2995	31
cd38 cd138 plasma	0.13	0.2	5207	71
cd38 cd138 plasma cell	1.89	0.1	9327	46

Search Results related to cd38xcd3 on Search Engine

Igm-2644, a Novel CD38xCD3 Bispecific IgM T Cell Engager …
ashpublications.org

https://ashpublications.org/blood/article/140/Supplement%201/6010/490359/Igm-2644-a-Novel-CD38xCD3-Bispecific-IgM-T-Cell

DA: 89 PA: 29 MOZ Rank: 36

Bispecific antibody treatment of multiple myeloma: latest updates …
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657518/

WEBNov 18, 2023 · Li K, Yun R, Chai M, et al. Igm-2644, a novel CD38xCD3 bispecific IgM T cell engager demonstrates potent efficacy on myeloma cells with an improved preclinical …

DA: 37 PA: 80 MOZ Rank: 6

Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018129/

DA: 68 PA: 84 MOZ Rank: 48

Abstract 2959: Novel CD38xCD3 bispecific IgM T cell engager, …
aacrjournals.org

https://aacrjournals.org/cancerres/article/83/7_Supplement/2959/723814/Abstract-2959-Novel-CD38xCD3-bispecific-IgM-T-cell

WEBApr 4, 2023 · Abstract 2959: Novel CD38xCD3 bispecific IgM T cell engager, IGM-2644, potently kills multiple myeloma cells though complement and T cell dependent …

DA: 66 PA: 56 MOZ Rank: 34

Dose Escalation of ISB 1342, a Novel CD38xCD3 Bispecific …
ashpublications.org

https://ashpublications.org/blood/article/142/Supplement%201/3339/503603/Dose-Escalation-of-ISB-1342-a-Novel-CD38xCD3

WEBNov 28, 2023 · Introduction: ISB 1342 is a humanized CD38xCD3 bispecific T-cell engager using Ichnos proprietary Bispecific Engagement by Antibodies based on the T cell …

DA: 70 PA: 46 MOZ Rank: 22

Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low …
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018129/

WEBApr 1, 2021 · Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma - PMC. Journal List. Haematologica. v.106 (4); 2021 Apr … Author: Maxime Fayon, Carolina Martinez-Cingolani, Audrey Abecassis, Nathalie Roders, Elisabeth Nelson, Caro... DOI: 10.3324/haematol.2019.242453 Publish Year: 2020 Publication: Haematologica. 2021 Apr 1; 106(4): 1193-1197.

Author: Maxime Fayon, Carolina Martinez-Cingolani, Audrey Abecassis, Nathalie Roders, Elisabeth Nelson, Caro...
DOI: 10.3324/haematol.2019.242453
Publish Year: 2020
Publication: Haematologica. 2021 Apr 1; 106(4): 1193-1197.

DA: 95 PA: 26 MOZ Rank: 70

P815: HIGH VALENCY OF IGM-2644, A CD38XCD3 IGM …
nih.gov

https://ncbi.nlm.nih.gov/pmc/articles/PMC10430526/

WEBAug 8, 2023 · P815: HIGH VALENCY OF IGM-2644, A CD38XCD3 IGM BISPECIFIC T CELL ENGAGER, DISPLACES DARATUMUMAB BINDING AND INDUCES POTENT …

DA: 90 PA: 64 MOZ Rank: 48

Dose Escalation of ISB 1342, a Novel CD38xCD3 ... - ScienceDirect
sciencedirect.com

https://www.sciencedirect.com/science/article/pii/S000649712309941X

WEBNov 2, 2023 · Introduction: ISB 1342 is a humanized CD38xCD3 bispecific T-cell engager using Ichnos proprietary Bispecific Engagement by Antibodies based on the T cell …

DA: 35 PA: 35 MOZ Rank: 84

Igm-2644, a Novel CD38xCD3 Bispecific IgM T Cell Engager …
semanticscholar.org

https://www.semanticscholar.org/paper/Igm-2644%2C-a-Novel-CD38xCD3-Bispecific-IgM-T-Cell-on-Li-Yun/03ad66be8c7a3ea5147105ff891576f5ff0e98ac

WEBNov 15, 2022 · Igm-2644, a Novel CD38xCD3 Bispecific IgM T Cell Engager Demonstrates Potent Efficacy on Myeloma Cells with an Improved Preclinical Safety Profile | Semantic …

DA: 22 PA: 96 MOZ Rank: 62

Glenmark Launches CD38xCD3 Phase 1 Trial for Bispecific …
americanpharmaceuticalreview.com

https://www.americanpharmaceuticalreview.com/1315-News/355309-Glenmark-Launches-CD38xCD3-Phase-1-Trial-for-Bispecific-Antibody-GBR-1342/

WEBNov 7, 2018 · Glenmark Pharmaceuticals announced the decision to launch a Phase 1 trial in solid tumors for its CD38xCD3 bispecific antibody GBR 1342. The decision is driven …

DA: 77 PA: 87 MOZ Rank: 24